This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

ICD-10 G31.04 — Primary progressive aphasia, NEC Special Copayment Reduction: V800

Primary progressive aphasia, NEC달리 분류되지 않은 원발성 진행성 실어증

Synonyms and related terms: Unclassifiable PPA, mixed PPA, progressive aphasia (not elsewhere classified), PPA-NEC

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Primary progressive aphasia (PPA) began to be recognized as an independent clinical entity in 1982, when Mesulam described a syndrome in which only language function progressively deteriorates without severe decline in other cognitive functions. Through decades of clinicopathological research, the 2011 international PPA classification criteria (Gorno-Tempini et al.) established a system classifying PPA into three main variants: nonfluent variant (nfvPPA), semantic variant (svPPA), and logopenic variant (lvPPA).

In clinical practice, however, there are not a few cases that do not fully meet the core criteria of the three variants, that show mixed features of two variants, or in which variant characteristics change during disease progression. Such cases are described as "unclassifiable PPA," "mixed PPA," or "PPA not elsewhere classified (PPA-NEC)," and are classified under ICD-10 code G31.04. G31.04 is a residual classification code covering PPA cases that do not belong to the three typical subtypes (G31.01 svPPA, G31.02 nfvPPA, G31.03 lvPPA).

2. Causes

G31.04 (PPA-NEC) is a heterogeneous group of cases that clinically meet the criteria for PPA but do not fully fit any of the three main variants. The underlying neuropathology is also varied: FTLD-TDP (types A, B, C), FTLD-tau (Pick disease, CBD, PSP, MAPT variant-related), Alzheimer pathology, and, rarely, FTLD-FUS. Multiple pathologies are therefore mixed within this code category rather than a single cause. In some cases, a case is initially classified as PPA-NEC and later reclassified as the features of a particular variant become clearer with disease progression.

The most common situations in PPA-NEC are ① cases with mixed features of nfvPPA and lvPPA (coexisting apraxia of speech + reduced phonological working memory), ② cases in the early stage in which the features needed for variant classification have not yet sufficiently appeared, and ③ cases in which the language disorder pattern does not fit a standard variant because of atypical lesion distribution. Rare FTLD subtypes (FTLD-FUS, FTLD-UPS, language phenotype of multiple system atrophy) can also be classified as PPA-NEC.

3. Genetics

The genetic architecture of PPA-NEC varies with the underlying pathology. In cases based on FTLD pathology, GRN variants, MAPT variants, and C9orf72 repeat expansion may be the cause, and in cases based on Alzheimer pathology, PSEN1, APP, and APOE ε4 are involved as risk factors. When there is a family history, an FTD gene panel (GRN, MAPT, C9orf72, TARDBP, FUS) and an AD gene panel (PSEN1, PSEN2, APP) are performed together. When a GRN variant is identified, plasma progranulin measurement is used as a screening test.

For some rare FTLD subtypes (FTLD-FUS: FUS, TARDBP variants; FTLD-UPS), the causative gene or pathogenic variant has not been sufficiently identified to date, so pathologic confirmation often depends on histopathology rather than genetic information. Genetic counseling for PPA-NEC patients should be provided individually, taking into account the unclear pathology and the various genetic possibilities.

4. General epidemiology

Data on the exact prevalence and incidence of PPA-NEC are limited. About 10-20% of all PPA is reported as unclassifiable or mixed type not fully classified into the three main variants, and these correspond to the G31.04 category. The age of onset is mainly in the 50s-70s, and the sex distribution is generally equal. The distribution of underlying pathology is varied, and the proportions of Alzheimer pathology, FTLD-TDP, and FTLD-tau differ depending on the characteristics of the clinical cohort.

With advances in diagnostic technology (amyloid PET, tau PET, plasma biomarkers), it is becoming possible to distinguish Alzheimer-based cases from FTLD-based cases within the PPA-NEC category during life, and judgment of treatment indications is improving accordingly. If biomarker-based classification becomes common in clinical practice in the future, use of the G31.04 category is expected to decrease.

5. Pathophysiology

The pathophysiology of PPA-NEC differs by underlying pathology and cannot be explained by a single pathophysiologic mechanism. In common, progressive neurodegeneration of the left-dominant language network is the core mechanism. The clinical phenotype is determined by which part of the corticosubcortical circuits involved in language processing - Broca's area (BA 44/45), Wernicke's area (BA 22), insula (BA 13), temporoparietal junction cortex (BA 39/40), and the basal ganglia-thalamic language circuit - is mainly affected.

Atypical lesion distribution and co-pathology create mixed symptom patterns that deviate from the standard variants. For example, when the left frontal lobe (nfvPPA feature) and temporoparietal lobe (lvPPA feature) are damaged simultaneously, a PPA-NEC pattern appears with mixed apraxia of speech and reduced phonological working memory. Cases in which the lesion has not progressed sufficiently in the early stage and the variant features are not clear are also classified as PPA-NEC and reclassified after progression.

6. Symptoms

The clinical symptoms of PPA-NEC are, by definition, a progressive language disorder that does not fully meet the core criteria of the three standard variants (svPPA, nfvPPA, lvPPA). In general it shows the pattern common to PPA: (1) gradual deterioration of language function, (2) relative preservation of other cognitive functions (memory, visuospatial, executive function) in early onset, and (3) decline in daily function mainly due to the language disorder.

In mixed cases, various language symptoms such as anomia, speech nonfluency, phonological errors, impaired sentence repetition, and impaired word comprehension appear in combination. It is often difficult to characterize the variant because no particular symptom is more prominent than the others, and it is important to identify the pattern of symptom progression over time through careful follow-up early in diagnosis. In some cases, behavioral symptoms, visuospatial decline, and motor symptoms accompany the language disorder early and the case is classified as PPA-NEC.

With progression, language decline deepens, other cognitive domains are also affected, and the disease finally progresses to a generalized neurodegenerative disease. Because the subsequent symptom pattern differs by the type of underlying pathology, biomarker-based confirmation of pathology is important for prognosis and treatment planning.

7. Signs

On neurological examination and neuropsychological testing, PPA-NEC shows a complex decline in language function rather than a single pattern specific to a particular variant. A complex pattern of decline is found on the naming test (BNT), sentence repetition test, word fluency tests (semantic, letter), observation of speech fluency, auditory comprehension test, and reading and writing tests. The patterns specific to particular variants (svPPA: early loss of semantic memory; nfvPPA: apraxia of speech and agrammatism; lvPPA: reduced phonological working memory and impaired sentence repetition) are unclear or mixed.

On brain MRI, left-predominant cortical atrophy is found, but it does not clearly fit the typical atrophy pattern of a particular variant (svPPA: anterior temporal lobe; nfvPPA: left posterior frontal-insular; lvPPA: left temporoparietal) or multiple areas are atrophied in combination. FDG-PET may also show a complex hypometabolism pattern. Confirming the type of underlying pathology through amyloid PET and CSF/plasma biomarkers is especially important for clinical decisions in PPA-NEC cases.

8. Screening

Screening for PPA-NEC is based on a standardized language test battery for PPA in general. Whether the variant can be characterized and whether a mixed pattern is present are assessed through a comprehensive language neuropsychological evaluation including the Boston Naming Test (BNT), Western Aphasia Battery (WAB), word fluency (semantic, letter), sentence repetition, short-term phonological memory, auditory comprehension, and reading and writing tests. The initial measurement of the PPA Severity Rating Scale is used as the baseline for follow-up.

For imaging, brain MRI (3T, high-resolution) assesses the location and extent of left language cortex atrophy, and FDG-PET provides topographic characteristics of the hypometabolism pattern. Amyloid PET or CSF Aβ42/p-tau biomarkers are essential for differentiating Alzheimer pathology-based PPA-NEC, and elevated plasma p-tau217 suggests an Alzheimer basis. When an FTD basis is suspected, elevated plasma NfL and GFAP, and decreased plasma progranulin in GRN variants, are used as adjunctive screening indicators.

9. Diagnosis

G31.04 (PPA-NEC) applies to cases that meet Mesulam's diagnostic criteria for primary progressive aphasia (gradual language decline for at least 2 years, relatively preserved non-language cognitive function, and language disorder as the main cause of decline in daily function) but do not fully fit any of the three variants of the 2011 international PPA classification criteria (G31.01 svPPA, G31.02 nfvPPA, G31.03 lvPPA). In the diagnostic process, the core and supportive criteria of the three variants should be checked systematically and whether they are met confirmed, after which it must be stated that none of the variants applies.

Imaging supportive criteria include left-predominant cortical atrophy on MRI and left language cortex hypometabolism on FDG-PET. Amyloid PET or CSF biomarkers (Aβ42/p-tau) are essential for determining whether there is an Alzheimer basis. Tau PET is used in research to detect FTLD-tau pathology (CBD, PSP, MAPT variant-related). Pathologic confirmation is made on autopsy tissue by Alzheimer criteria or FTLD criteria (TDP-43, tau, FUS immunohistochemistry). When using the G31.04 code in diagnosis, it is recommended to state "does not correspond to any variant" in the clinical record and to record the biomarker results together.

10. Treatment

There is no disease-modifying treatment for PPA-NEC, and treatment is centered on individualized symptomatic therapy according to the type of underlying pathology and the clinical phenotype. For Alzheimer pathology-based (amyloid PET-positive) PPA-NEC, treatment with anti-amyloid monoclonal antibodies (lecanemab, donanemab) can be considered if the treatment indication criteria (A+ confirmed, CDR 0.5-1 stage) are met. Cholinesterase inhibitors may be used empirically in Alzheimer-based cases, but PPA-specific evidence is limited.

In FTLD-based PPA-NEC, SSRIs (with behavioral symptoms) and low-dose atypical antipsychotics (for severe agitation) are used as needed. Speech-language therapy is recommended for all PPA regardless of variant, and includes strategies using residual language function, introduction of augmentative and alternative communication (AAC), voice banking, and family communication training. Occupational therapy, physical therapy, and social welfare linkage are provided through the integrated approach of the multidisciplinary team.

11. Prognosis

The prognosis of PPA-NEC varies with the type of underlying pathology and lesion distribution. Cases based on Alzheimer pathology show a course of 8-12 years similar to typical AD, and a survival of 6-12 years is reported for FTLD-based cases. Prognosis is more difficult to predict in cases with mixed pathology or atypical lesion distribution. In common, progressive loss of language function is followed by global cognitive decline, and in the late stage the patient becomes mute, has dysphagia, and is completely dependent for daily function.

The PPA Severity Rating Scale, the WAB Aphasia Quotient (AQ), and the CDR plus FTLD sum of boxes score are used to track functional level. Elevated plasma NfL is used as a surrogate indicator of the rate of neurodegeneration, and higher baseline NfL is associated with faster progression. Biomarker-based confirmation of pathology (amyloid PET, tau PET, plasma biomarkers) is becoming increasingly important for prognosis and treatment planning. Advance care planning, preparation of a life-sustaining treatment plan, AAC planning, and hospice linkage should be led by the multidisciplinary team early in diagnosis.

12. Prevention

There is no established primary prevention for PPA-NEC. For Alzheimer-based PPA-NEC, management of modifiable Alzheimer risk factors has preventive significance, and in FTLD-based cases, family genetic counseling and predictive testing are offered when a familial causative variant is identified. For general brain health maintenance, management of cardiovascular risk factors, regular exercise, social participation, and prevention of head trauma are recommended. Early diagnosis and establishing an appropriate treatment plan through biomarker-based confirmation of pathology contribute to maintaining quality of life for patients and families.

13. References